Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
… ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
… Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
… Axiomer ® RNA editing technology platform and continued advancement of pipeline LEIDEN, Netherlands & CAMBRIDGE, … Officer of ProQR. “We look forward to continuing to advance our Axiomer RNA editing platform, with an initial … ® , which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to …
… there is currently no treatment,” said Dr. Bart Leroy, Head of the Ophthalmology Department and Professor of … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …
… Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …